Document Detail

Disposition of nitrendipine in patients with chronic liver diseases.
MedLine Citation:
PMID:  2468869     Owner:  NLM     Status:  MEDLINE    
Metabolism of nitrendipine occurs principally in the liver. Therefore, an alteration of pharmacokinetics has to be discussed in patients with hepatic impairment. To evaluate steady-state plasma concentrations and pharmacokinetics, a low dose of nitrendipine (5 mg/day for 3 weeks) was administered orally to patients with different chronic liver diseases (fatty liver, n = 3; chronic hepatitis, n = 2; and cirrhosis of the liver, n = 5). Nitrendipine plasma concentrations were analyzed by using a gas-liquid chromatography procedure. Twenty-two days after beginning the study, steady-state plasma concentrations were lower than 1.0 microgram/L in one patient without liver disease and in seven patients with chronic liver diseases, in contrast to three patients with alcoholic cirrhosis (5.5, 1.3, and 2.9 micrograms/L). The maximum concentration (Cmax) was 2.3 micrograms/L in the patient without liver disease and 8.3 +/- 3.9 micrograms/L in the hepatic patients. The elimination half-life was prolonged in three of five patients with cirrhosis of the liver (35, 67, and 43 h), whereas in the other patients the half-life was in a normal range (4.2-21.3 h). The area under the concentration-time curve (AUC) was enhanced in three patients with liver cirrhosis (387, 69, and 126 h/micrograms/L); in the other seven hepatic patients, results were normal (35-49 h/micrograms/L). There were no alterations observed in any patient in blood pressure and laboratory data. Oral administration of a low dose of nitrendipine resulted in slightly enhanced steady state plasma concentrations only in patients with advanced cirrhosis of the liver. The half-life, AUC, and bioavailability also seem to be altered only in a more severe state of liver disease.
W Zilly; K D Rämsch; M Gothe
Related Documents :
14767999 - The effect of hypertonic sodium chloride on intracranial pressure in patients with acut...
1816219 - Autonomic function tests and clinical significance of dysautonomia in chronic liver dis...
9189129 - Clinical impact of somatostatin receptor scintigraphy in the management of patients wit...
2010309 - Immunoscintigraphy using different methods of applying a 99mtc labeled monoclonal anti-...
3917969 - Pattern and prognosis of liver function test abnormalities during parenteral nutrition ...
15660829 - Red blood cell exchange transfusion in two patients with advanced erythropoietic protop...
16297469 - Treatment and outcome of biopsy-proven fulminant myocarditis in adults.
11206869 - Intrapulmonary vascular dilatation in portal hypertension due to cirrhosis of liver.
2152459 - Non-traumatic chest pain in young adults: a medical audit.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  12 Suppl 4     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1988  
Date Detail:
Created Date:  1989-06-05     Completed Date:  1989-06-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S175-7     Citation Subset:  IM    
Hartwald-Klinik der BfA, Bad Brückenau, F.R.G.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Availability
Chromatography, Gas
Chronic Disease
Liver Diseases / metabolism*
Middle Aged
Nitrendipine / blood,  pharmacokinetics*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acute and chronic effects of nitrendipine on hemodynamics and myocardial ischemia in patients with c...
Next Document:  24-hour noninvasive oscillometric blood pressure monitoring: evaluation of the antihypertensive circ...